Dianthus Therapeutics (DNTH) Operating Income (2017 - 2025)
Historic Operating Income for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$40.3 million.
- Dianthus Therapeutics' Operating Income fell 3474.25% to -$40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.3 million, marking a year-over-year decrease of 6924.15%. This contributed to the annual value of -$101.9 million for FY2024, which is 11145.02% down from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' Operating Income is -$40.3 million, which was down 3474.25% from -$34.9 million recorded in Q2 2025.
- Dianthus Therapeutics' Operating Income's 5-year high stood at -$7.7 million during Q1 2023, with a 5-year trough of -$40.3 million in Q3 2025.
- Moreover, its 4-year median value for Operating Income was -$17.8 million (2024), whereas its average is -$21.3 million.
- Per our database at Business Quant, Dianthus Therapeutics' Operating Income plummeted by 2116.34% in 2023 and then plummeted by 14634.15% in 2024.
- Quarter analysis of 4 years shows Dianthus Therapeutics' Operating Income stood at -$10.7 million in 2022, then decreased by 21.16% to -$13.0 million in 2023, then crashed by 146.34% to -$31.9 million in 2024, then dropped by 26.23% to -$40.3 million in 2025.
- Its Operating Income was -$40.3 million in Q3 2025, compared to -$34.9 million in Q2 2025 and -$33.2 million in Q1 2025.